Possible new AED(s)

Welcome to the Coping With Epilepsy Forums

Welcome to the Coping With Epilepsy forums - a peer support community for folks dealing (directly or indirectly) with seizure disorders. You can visit the forum page to see the list of forum nodes (categories/rooms) for topics.

Please have a look around and if you like what you see, please consider registering an account and joining the discussions. When you register an account and log in, you may enjoy additional benefits including no ads, access to members only (ie. private) forum nodes and more. Registering an account is free - you have nothing to lose!

Bernard

Your Host
Administrator
Benefactor
Messages
7,392
Reaction score
738
Points
278
Bloomberg said:
Schwarz Pharma AG, a German generic-drug maker moving into branded medicines, said its experimental epilepsy treatment met the main goals of late-stage clinical tests. ...

The study confirmed data obtained from an earlier clinical trial on adult patients suffering partial seizures who were given the medicine, the Monheim, Germany-based drugmaker said in a statement to the Frankfurt stock exchange today. The company plans to use the study to apply for marketing approval of the drug, called Lacosamide.

Lacosamide is the most promising of three drugs Schwarz Pharma is developing in its own laboratories. The company has said it expects to garner sales of as much as $1 billion a year from the medicine, which may also help treat neuropathic pain. ...

...

Analysts including Dresdner Kleinwort Wasserstein's Tero Weckroth have said Lacosamide may generate more revenue than the company forecasts because its side effects are less unpleasant than those of its main rival Lyrica, introduced to the market by Pfizer Inc. last April.

Chief Executive Officer Patrick Schwarz-Schuette is considering selling some rights to the drug to maximize the product's sales potential.

``We will take a decision by the end of the year,'' Schwarz-Schuette said in an interview in February. ``There's a lot of interest, and I'm open to negotiations. But we won't decide until we have all the data and have submitted our application for approval.''

Schwarz Pharma Says Epilepsy Drug Met Trial Goals (Update2)
 
Back
Top Bottom